IDENTIFICATION OF A POTENTIAL CYTOGENETIC MARKER

描述：(改编自调查人员摘要)前列腺癌 是导致美国男性癌症死亡的第二大原因 各州。诊断试验的最新进展，如超声和 磁共振成像，加上改进的活组织检查技术和 血清学测试使早期发现这种疾病成为可能。 没有症状的男人。然而，这种疾病的早期发现也会造成 由于缺乏可以在临床上区分的测试而造成的治疗困境 显性肿瘤来自潜伏性肿瘤。协助临床管理 对于前列腺癌患者，有必要识别一种 生物标记，可用于区分潜在的 来自潜伏肿瘤的侵袭性肿瘤。我们最近确认了 一种细胞遗传学标记(即，7三体)，与 人类前列腺癌进展到晚期和转移 网站。对36例前列腺标本的初步研究表明， 7三体细胞的频率随着肿瘤分期的增加而增加。 肿瘤。此外，转移瘤显示出更高的三体频率。 7个细胞，而不是原发肿瘤。最有趣的是，在两名患有 配对原发和转移性肿瘤，7三体细胞从4-7%增加 在原发肿瘤中，42-45%在骨转移瘤细胞中 骨髓。因此，数据表明，7三体可能是一种常见的 与人类局部和转移进展相关的特征 前列腺癌作为人类前列腺癌的新标记物 进步。在这项提案中，调查员将审查 7三体和其他潜在的前列腺癌遗传标记的有用性 肿瘤进展，例如，8号染色体的新生和丢失 7q31基因座杂合性在预测肿瘤行为和预后中的作用 预后。我们还将比较独立预测值 这些遗传标记与肿瘤分级、分期和倍性的多变量 分析。一个可靠的遗传标记的鉴定将使 临床医生对患有慢性阻塞性肺疾病的患者使用不同的治疗策略 癌症进展的不同风险。例如，有一种 进展/转移的基因标记物可能被积极治疗 前列腺癌切除术后化疗以消除微转移和 以降低疾病复发的风险。相反，病人 那些没有进展标记的人可能会免于副作用 与治疗有关。

DESCRIPTION: (adapted from the investigator's abstract) Prostate cancer is the second leading cause of cancer deaths among men in the United States. Recent advances in diagnostic tests such as ultrasound and magnetic resonance imaging, coupled with improved biopsy techniques and serologic tests, have made possible early detection of this disease in asymptomatic men. However, early detection of this disease also creates treatment dilemmas due to lack of tests that can distinguish clinically significant tumors from latent tumors. To aid in the clinical management of prostate cancer patients, there is a need for identification of a biological marker that could be used to distinguish potentially aggressive tumors from latent tumors. We have recently identified a cytogenetic marker (i.e., trisomy 7) that is associated with the progression of human prostate cancer to advanced stages and to metastatic sites. Preliminary studies on 36 prostate specimens showed that the frequency of cells with trisomy 7 increased with increasing stages of the tumor. Furthermore, metastases showed a higher frequency of trisomy 7 cells than primary tumors. Most interestingly, in two patients with paired primary and metastatic tumors, trisomy 7 cells increased from 4-7% in the primary tumors to 42-45% in the metastatic tumor cells in the bone marrow. Therefore, the data suggests that trisomy 7 may be a common feature associated with the local and metastatic progression of human prostate cancer and serve as a novel marker for human prostate cancer progression. In this proposal, the investigator will examine the usefulness of trisomy 7, and other potential genetic markers for prostate tumor progression, e.g., aneusomy of chromosome 8 and loss of heterozygosity of genetic loci on 7q31, in predicting tumor behavior and prognosis. We will also compare the independent predictive values of these genetic markers with tumor grade, stage, and ploidy in multivariate analyses. The identification of a reliable genetic marker would allow clinicians to use different treatment strategies for patients who have different risks of cancer progression. For example, patients who have a genetic marker for progression/metastasis may be aggressively treated with chemotherapy after prostatectomy to eliminate micrometastasis and to reduce the risk of recurrence of the disease. Conversely, patients who do not have the progression markers may be spared the side effects associated with therapy.